SRH Advisors’s Acorda Therapeutics ACOR Stock Holding History

SRH Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-15	Closed	-$36K	–	289
2018 Q3	$36K	Hold	15	–	–	0.12%	102
2018 Q2	$53K	Buy	+15	New	+$45.9K	0.2%	81

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SRH Advisors's ACOR Position: Q4 2018 in Review

SRH Advisors sold out of Acorda Therapeutics (ACOR) in Q4 2018, closing a stake of 15 shares — an estimated $36K sold.

SRH Advisors first reported a position in ACOR in Q2 2018 and held it in 2 quarters. The position peaked at $53K in Q2 2018. 179 funds tracked by Wall St. Rank hold ACOR as of Q4 2018.

SRH Advisors reported no remaining Acorda Therapeutics position as of Q4 2018 after selling out during the quarter.
SRH Advisors sold 15 Acorda Therapeutics shares in Q4 2018, an estimated $36K.
SRH Advisors first reported a position in Acorda Therapeutics in Q2 2018 and held it in 2 quarters.
SRH Advisors's Acorda Therapeutics position peaked at $53K in Q2 2018.
179 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2018.

Based on SRH Advisors's 13F filing for Q4 2018, filed 22 Jan 2019.